Market Segmentation:
- By Product Type
- Oral Medications
- Injectable Medications
- Penile Implants
- Vacuum Devices
- Others (Topical Creams, Suppositories)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Clinics
- Mail-order
- Others (Specialty Pharmacies, Direct-to-Patient)
- By Age Group
- Below 30 Years
- 30-50 Years
- 51-70 Years
- Above 70 Years
- By Disease Indication
- Diabetes
- Cardiovascular Diseases
- Neurological Disorders
- Prostate Cancer
- Others (Kidney Diseases, Hormonal Imbalances)
- By End User
- Hospitals
- Clinics
- Home Care Settings
- Others (Research Institutes, Academic Centers)
- By Drug Type
- Branded Drugs
- Generic Drugs
- By Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Erectile Dysfunction industry is estimated to be around US$ 3.2 billion.
Increasing prevalence of chronic diseases, aging population, changing lifestyles, growing awareness, availability of new treatment options, advancements in diagnostics, and increasing healthcare expenditure.
High cost of branded treatments, strict regulatory guidelines, social stigma and cultural barriers, side effects of existing treatments, lack of awareness in developing regions, and limited access to healthcare facilities.
The leading component segment in the Erectile Dysfunction Market is oral medications, which offer convenience and efficacy for ED treatment.
Pfizer Inc., Eli Lilly and Company, Bayer AG, Allergan plc (acquired by AbbVie Inc.), Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Novartis AG, and Bristol-Myers Squibb Company.
The Global Erectile Dysfunction Market is expected to reach US$ 6.2 Bn in 2031 with a growth rate of 8.6%
Increasing prevalence of chronic diseases, aging population, changing lifestyles, growing awareness, availability of new treatment options, advancements in diagnostics, and increasing healthcare expenditure.